PROSTATE ADENOCARCINOMA

This study tests a new type of focused radiation (SBRT) to treat early-stage prostate cancer that hasn't spread. The goal is to destroy only the tumor, not the whole prostate, which may reduce side effects like incontinence and impotence. About 42 men will receive two painless ra…

This study tests a type of internal radiation therapy (HDR-BT) that targets only the tumor in the prostate, rather than the whole gland. The goal is to control the cancer while reducing long-term urinary and sexual problems often caused by standard treatments. About 45 men with e…

This early-phase study tests a personalized approach to radiation therapy for men with high-risk prostate cancer. It uses special PET scans to see how tumors respond to hormone therapy and then adjusts the timing of radiation boosts. The goal is to improve tumor shrinkage while r…

This study tests whether adding the drug apalutamide to usual hormone therapy and radiation can keep prostate cancer from spreading in men whose cancer reached lymph nodes after prostate removal surgery. About 586 men will be randomly assigned to get either standard treatment alo…

This study looks at men whose prostate cancer has come back in a few spots after radiation therapy. It compares two approaches: targeted treatment alone versus targeted treatment plus a hormone-blocking drug (ELIGARD). The goal is to see which combination delays cancer progressio…

This study tests a newer, more precise type of radiation therapy (SABR) for men with low to high-risk prostate cancer. The goal is to see if this approach can control the cancer while reducing side effects like urinary and bowel problems. About 136 men will receive the treatment …

This study tests whether adding the drug relacorilant to standard hormone therapy and enzalutamide can better shrink high-risk prostate cancer before surgery. About 90 men with advanced, localized prostate cancer that hasn't spread will take the drug combination or a placebo for …

This study compares a new, shorter radiation treatment (5 sessions over 2 weeks) to the standard longer treatment (20 to 45 sessions over 4 to 9 weeks) for men with high-risk prostate cancer. The goal is to see if the shorter course works just as well at preventing the cancer fro…

This study tests whether special PET scans (PSMA or fluciclovine) can find small areas of prostate cancer that have spread beyond the prostate. If found, doctors will treat those spots directly with radiation or surgery. The goal is to lower PSA levels and delay the need for long…

This study compares two hormone therapies, Orgovyx and Eligard, used alongside radiation for prostate cancer. The goal is to see which one is less harmful to the heart. About 70 men with intermediate-risk prostate cancer will take one of the drugs for 6 months and undergo heart t…

This study tests whether adding two hormone-blocking drugs (relugolix and enzalutamide) to radiation therapy can better control very-high-risk prostate cancer. About 50 men will receive the combination for 18 months. The main goal is to see if cancer cells disappear from biopsy s…

This study tests whether a special 5-day monthly diet that mimics fasting can improve how well standard prostate cancer treatments work. About 138 men with advanced prostate cancer will either follow this diet or eat normally for 6 months. The goal is to see if the diet helps low…

This study tests whether a single dose of a radioactive drug (Lu-177-PSMA-617) given before surgery can shrink or eliminate high-risk prostate cancer. About 54 men with aggressive prostate cancer will receive the drug, then have their prostate removed. The goal is to see if the c…

This study is for men whose prostate cancer has returned after surgery, shown by a rising PSA level. It tests whether adding a stronger drug combination (apalutamide plus abiraterone and prednisone) to standard radiation and hormone therapy can better control the cancer. For thos…

This study tests a new type of radiation for prostate cancer that has spread to lymph nodes in the abdomen or pelvis. About 26 men will receive targeted, high-dose radiation that adapts to the tumor's shape each day. The goal is to control the cancer while reducing side effects o…

This study tests whether giving the chemotherapy drug carboplatin before surgery can shrink tumors in men with high-risk prostate cancer who have inherited BRCA1 or BRCA2 gene mutations. About 44 participants will receive carboplatin before their prostate surgery. The goal is to …

This study tests whether a daily supplement called urolithin A can lower cell damage (oxidative stress) in prostate tumors. About 90 men with prostate cancer will take either the supplement or a placebo for 3 to 6 weeks before their prostate removal surgery. The goal is to see if…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer and other solid tumors that have spread or cannot be removed. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 470 adults will take part.

This study compares two modern treatments for men with low-to-intermediate risk prostate cancer that hasn't spread: a robotic partial prostatectomy (removing part of the prostate through a single port) and high-intensity focused ultrasound (HIFU, which uses sound waves to destroy…

This early-stage study tests a small implant called Enolen that releases the drug enzalutamide directly into the prostate. The goal is to see if it is safe and can deliver high drug levels to the tumor while reducing side effects. About 56 men with prostate cancer who are already…

This study is for people with high-risk prostate cancer that has spread to a few other spots. It tests whether giving less hormone therapy (based on each person's risk) along with radiation can control the cancer just as well as the standard longer hormone therapy. The goal is to…

This study tests a new treatment for men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The treatment combines a hormone therapy (testosterone) with a radioactive drug (radium-223) to try to slow cancer growth. About 47 men will recei…

This study looks at whether adding a special PET/CT scan (rhPSMA-7.3) to the usual MRI can find more aggressive prostate cancers in men who are currently just watching their low-risk cancer. About 120 men will get both scans before a confirmatory biopsy. The goal is to see if the…

This study compares a new personalized biopsy method that uses fewer needle samples to the standard method for diagnosing prostate cancer. The goal is to see if the new approach can detect dangerous cancers just as well while causing less bleeding, pain, and infection. About 330 …

This study is testing a new computer software that creates risk maps from MRI scans to help doctors decide if a prostate biopsy is needed. About 180 people with known or suspected prostate cancer will have one MRI and one or two biopsies, and be followed for a year. The goal is t…

This study tests a new type of PET/CT scan using a radioactive tracer called copper Cu 64 PSMA I&T to see if it can accurately find prostate cancer that has spread to pelvic lymph nodes. About 439 men with newly diagnosed, high-risk prostate cancer who are planning to have their …

This study tests whether taking a hormone-blocking drug (relugolix) for a few days before a PSMA PET/CT scan can make prostate cancer cells more visible. The goal is to improve detection of cancer that has spread to lymph nodes in men with high-risk prostate cancer. About 30 part…

This study compares two different radiation schedules for men with low-risk prostate cancer: the standard five treatments versus a shorter course of just two treatments. The goal is to see if the shorter course can maintain sexual quality of life just as well, while still control…

This study tests a drug called fezolinetant to see if it can reduce hot flashes in men with prostate cancer who are on hormone therapy (ADT). About 60 men will take either the drug or a placebo daily for 4 weeks. Researchers will track hot flash frequency, severity, and any liver…

This study looks at whether giving cancer treatment at home instead of a hospital can help Black men with advanced prostate cancer feel better and have fewer health disparities. About 77 Black men will try patient-centered home care and share their experiences through surveys. Th…

This study tests a new proton therapy technique called 'Spot Delete' for men with low- to intermediate-risk prostate cancer. The goal is to reduce bowel and bladder side effects by preventing proton beams from stopping in sensitive areas. The study will enroll 500 participants an…

This study tests whether using a special dye (ICG) during robotic prostate surgery helps preserve sexual function and bladder control in men with prostate cancer. About 400 men will take part, and the main goal is to see how many need little to no pads for urine leakage three mon…

This study looks at whether personalized nutrition and exercise plans can help reduce frailty and improve body composition in prostate cancer survivors who are on hormone therapy (androgen deprivation therapy). About 50 participants will receive tailored advice and be monitored f…

This study tests a special MRI scan that uses a natural substance (hyperpolarized pyruvate) to see how active prostate cancer cells are. It involves 60 men with low- to intermediate-risk prostate cancer who are not receiving treatment but are being watched closely (active surveil…

This study looks at how hormone therapy changes PSMA levels in men with prostate cancer. Researchers want to find the best time to do a PSMA PET scan after starting treatment. About 80 men with either castration-sensitive or castration-resistant prostate cancer will take part. Th…

This study compares two standard treatments for high-risk prostate cancer that hasn't spread: robot-assisted surgery and radiation therapy (often with hormone therapy). The goal is to see which approach better preserves quality of life, urinary and sexual function, and prevents t…

This study looks at whether markers in the blood can tell doctors if a man's advanced prostate cancer will respond to hormone therapy. Researchers will collect blood samples from 120 men with metastatic castration-resistant prostate cancer during their standard treatment. They wi…